journal
MENU ▼
Read by QxMD icon Read
search

Lancet HIV

journal
https://www.readbyqxmd.com/read/29731408/hiv-and-cardiovascular-disease-defining-the-unmeasured-risk
#1
Padraig M C McGettrick, Patrick W G Mallon
No abstract text is available yet for this article.
May 3, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29731407/cardiovascular-disease-and-use-of-contemporary-protease-inhibitors-the-d-a-d-international-prospective-multicohort-study
#2
Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft
BACKGROUND: Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted darunavir were associated with increased incidence of cardiovascular disease in people living with HIV. METHODS: The prospective Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study consists of people living with HIV-1 from 11 cohorts in Australia, Europe, and the USA...
May 3, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29703707/reliability-of-hiv-rapid-diagnostic-tests-for-self-testing-compared-with-testing-by-health-care-workers-a-systematic-review-and-meta-analysis
#3
Carmen Figueroa, Cheryl Johnson, Nathan Ford, Anita Sands, Shona Dalal, Robyn Meurant, Irena Prat, Karin Hatzold, Willy Urassa, Rachel Baggaley
BACKGROUND: The ability of individuals to use HIV self-tests correctly is debated. To inform the 2016 WHO recommendation on HIV self-testing, we assessed the reliability and performance of HIV rapid diagnostic tests when used by self-testers. METHODS: In this systematic review and meta-analysis, we searched PubMed, PopLine, and Embase, conference abstracts, and additional grey literature between Jan 1, 1995, and April 30, 2016, for observational and experimental studies reporting on HIV self-testing performance...
April 24, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29703706/accelerating-epidemic-control-the-role-of-hiv-self-testing
#4
Noah Kojima, Jeffrey D Klausner
No abstract text is available yet for this article.
April 24, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29653916/nutritional-support-to-reduce-mortality-in-patients-with-hiv
#5
George PrayGod, Henrik Friis, Suzanne Filteau
No abstract text is available yet for this article.
April 10, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29653915/effect-of-ready-to-use-supplementary-food-on-mortality-in-severely-immunocompromised-hiv-infected-individuals-in-africa-initiating-antiretroviral-therapy-reality-an-open-label-parallel-group-randomised-controlled-trial
#6
Jane Mallewa, Alexander J Szubert, Peter Mugyenyi, Ennie Chidziva, Margaret J Thomason, Priscilla Chepkorir, George Abongomera, Keith Baleeta, Anthony Etyang, Colin Warambwa, Betty Melly, Shepherd Mudzingwa, Christine Kelly, Clara Agutu, Helen Wilkes, Sanele Nkomani, Victor Musiime, Abbas Lugemwa, Sarah L Pett, Mutsa Bwakura-Dangarembizi, Andrew J Prendergast, Diana M Gibb, A Sarah Walker, James A Berkley
BACKGROUND: In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-to-use supplementary food (RUSF) would increase early weight gain, thereby reducing early mortality compared with current guidelines recommending ready-to-use therapeutic food (RUTF) for severely malnourished individuals only. METHODS: We did a 2 × 2 × 2 factorial, open-label, parallel-group trial at inpatient and outpatient facilities in eight urban or periurban regional hospitals in Kenya, Malawi, Uganda, and Zimbabwe...
April 10, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29650452/hiv-incidence-and-scale-up-of-prevention-in-western-kenya
#7
Nelson K Sewankambo
No abstract text is available yet for this article.
April 9, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29650451/hiv-incidence-in-western-kenya-during-scale-up-of-antiretroviral-therapy-and-voluntary-medical-male-circumcision-a-population-based-cohort-analysis
#8
Martien W Borgdorff, Daniel Kwaro, David Obor, George Otieno, Viviane Kamire, Frederick Odongo, Patrick Owuor, Jacques Muthusi, Lisa A Mills, Rachael Joseph, Mary E Schmitz, Peter W Young, Emily Zielinski-Gutierrez, Kevin M De Cock
BACKGROUND: In Kenya, coverage of antiretroviral therapy (ART) among people with HIV infection has increased from 7% in 2006, to 57% in 2016; and, in western Kenya, coverage of voluntary medical male circumcision (VMMC) increased from 45% in 2008, to 72% in 2014. We investigated trends in HIV prevalence and incidence in a high burden area in western Kenya in 2011-16. METHODS: In 2011, 2012, and 2016, population-based surveys were done via a health and demographic surveillance system and home-based counselling and testing in Gem, Siaya County, Kenya, including 28 688, 17 021, and 16 772 individuals aged 15-64 years...
April 9, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29592840/doravirine-versus-ritonavir-boosted-darunavir-in-antiretroviral-naive-adults-with-hiv-1-drive-forward-48-week-results-of-a-randomised-double-blind-phase-3-non-inferiority-trial
#9
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Xia Xu, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, Bach-Yen Nguyen, George J Hanna, Carey Hwang
BACKGROUND: Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two nucleoside reverse transcriptase inhibitors (NRTIs), in adults with previously untreated HIV-1 infection. METHODS: In this randomised, controlled, double-blind, multicentre, non-inferiority trial, adults with HIV-1 infection were screened and enrolled at 125 clinical centres in 15 countries...
March 23, 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739700/catalysing-the-development-and-introduction-of-paediatric-drug-formulations-for-children-living-with-hiv-a-new-global-collaborative-framework-for-action
#10
Martina Penazzato, Melynda Watkins, Sébastien Morin, Linda Lewis, Fernando Pascual, Marissa Vicari, Janice Lee, Sally Hargreaves, Meg Doherty, George K Siberry
Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and children is suboptimal. Of the children living with HIV globally (most in Africa), only 43% are receiving antiretroviral therapy (ART), many with suboptimal formulations. These shortfalls pose a series of challenges to meeting global treatment targets of 1·6 million children (aged 0-14 years) on ART by the end of 2018 (95% coverage) and to ensuring that 95% of those on ART are virologically suppressed...
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739699/early-antiretroviral-therapy-in-hiv-infected-infants-can-it-lead-to-hiv-remission
#11
REVIEW
Stephanie Shiau, Elaine J Abrams, Stephen M Arpadi, Louise Kuhn
Interventions to prevent mother-to-child HIV transmission have been extremely successful, but new HIV infections continue to occur in infants. Strong evidence indicates that combination antiretroviral therapy (ART) for treatment should be started in HIV-infected infants to prevent early morbidity and mortality. In 2013, the report of the Mississippi baby, who was started on ART within 30 h of life and maintained off-treatment remission for 27 months before HIV was once again detectable, generated renewed interest in very early ART initiation...
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739698/dean-street-clinics-battling-london-s-msm-hiv-epidemic
#12
Tony Kirby, Michelle Thornber-Dunwell
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739697/highlights-of-the-25th-croi
#13
Peter Hayward
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739696/uk-sexual-health-services-struggle-with-public-health-cuts
#14
Tony Kirby
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739695/prioritisation-of-subgroups-for-immediate-antiretroviral-therapy
#15
LETTER
Zunyou Wu, Yan Zhao, Jennifer McGoogan
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739694/prioritisation-of-subgroups-for-immediate-antiretroviral-therapy-authors-reply
#16
LETTER
Jean-Michel Molina, Birgit Grund
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29739693/will-redfield-s-hiv-background-prepare-him-for-top-cdc-job
#17
EDITORIAL
The Lancet Hiv
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29643012/dolutegravir-intensification-and-hiv-persistence-3-1-3
#18
Timothy J Henrich
No abstract text is available yet for this article.
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29643011/the-effect-of-antiretroviral-intensification-with-dolutegravir-on-residual-virus-replication-in-hiv-infected-individuals-a-randomised-placebo-controlled-double-blind-trial
#19
Thomas A Rasmussen, James H McMahon, J Judy Chang, Jennifer Audsley, Ajantha Rhodes, Surekha Tennakoon, Ashanti Dantanarayana, Tim Spelman, Tina Schmidt, Stephen J Kent, Vincent Morcilla, Sarah Palmer, Julian H Elliott, Sharon R Lewin
BACKGROUND: Whether ongoing virus replication occurs in HIV-infected individuals on antiretroviral therapy (ART) is unclear; therefore, whether residual virus replication is a barrier to achieving a cure for HIV is also unknown. We aimed to establish whether ART intensification with dolutegravir would reveal or affect residual virus replication in HIV-infected individuals on suppressive treatment. METHODS: In this randomised, placebo-controlled, double-blind trial, we enrolled HIV-infected adults (aged 18 years and older) receiving combination ART (at least three agents) for at least 3 years from the Alfred Hospital and Melbourne Sexual Health Centre, Melbourne, VIC, Australia...
May 2018: Lancet HIV
https://www.readbyqxmd.com/read/29592841/will-nnrtis-be-driving-forward-again
#20
Alexandra Calmy, Philip E Tarr
No abstract text is available yet for this article.
May 2018: Lancet HIV
journal
journal
49635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"